PRS 050
Alternative Names: Angiocal; PRS-050; PRS-050-PEG40Latest Information Update: 17 Dec 2024
Price :
$50 *
At a glance
- Originator Pieris
- Developer Palvella Therapeutics
- Class Antineoplastics
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours